Veracyte Company Insiders

VCYT Stock  USD 26.78  0.00  0.00%   
Veracyte's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Veracyte suggests that vertually all insiders are panicking. Veracyte employs about 824 people. The company is managed by 17 executives with a total tenure of roughly 25 years, averaging almost 1.0 years of service per executive, having 48.47 employees per reported executive.
Bonnie Anderson  CEO
Co-Founder, CEO and President Director and Member of Non-Management Equity Award Committee

Insider Sentiment 0

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2025-02-03Rebecca ChambersDisposed 527 @ 43.85View
2025-01-02Karin EasthamDisposed 10000 @ 40.3View
2024-12-03Rebecca ChambersDisposed 7000 @ 43.23View
2024-11-27Jonathan WygantDisposed 5032 @ 42.89View
2024-09-19Evan/ Fa JonesDisposed 5173 @ 35.23View
2024-09-04John LeiteDisposed 5479 @ 29.78View
2024-08-13Evan/ Fa JonesDisposed 20457 @ 32.2View
2024-08-09Evan/ Fa JonesDisposed 1032 @ 30.03View
2024-08-07Jens HolsteinDisposed 5000 @ 29View
2024-07-16Karin EasthamDisposed 7500 @ 25View
Monitoring Veracyte's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Veracyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.

Veracyte Management Team Effectiveness

The company has return on total asset (ROA) of 0.0194 % which means that it generated a profit of $0.0194 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0286 %, meaning that it created $0.0286 on every $100 dollars invested by stockholders. Veracyte's management efficiency ratios could be used to measure how well Veracyte manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Veracyte's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 1.4 B in 2025, whereas Non Current Liabilities Other is likely to drop slightly above 923.4 K in 2025.
Common Stock Shares Outstanding is likely to drop to about 44.7 M in 2025. Net Loss is likely to drop to about (34.5 M) in 2025

Veracyte Workforce Comparison

Veracyte is rated first in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 104,999. Veracyte maintains roughly 824 in number of employees contributing less than 1% to equities under Health Care industry.
The company has Profit Margin (PM) of 0.07 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.07 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.07.

Veracyte Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Veracyte insiders, such as employees or executives, is commonly permitted as long as it does not rely on Veracyte's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Veracyte insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Veracyte Notable Stakeholders

A Veracyte stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Veracyte often face trade-offs trying to please all of them. Veracyte's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Veracyte's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Bonnie AndersonCo-Founder, CEO and President Director and Member of Non-Management Equity Award CommitteeProfile
Corinne DananSenior PresidentProfile
Rebecca ChambersExecutive CFOProfile
Tina NovaDirectorProfile
Shayla GormanDirector RelationsProfile
Robert BraininExecutive OfficerProfile
John LeiteChief BusinessProfile
Annie McGuireSr CounselProfile
Tracy MorrisVP CommunicationsProfile
Keith GligorichSenior OperationsProfile
Jonathan WygantVP OfficerProfile
Phillip MDChief OfficerProfile
Beverly CPAVP ControllerProfile
Karen PossematoCommunications MarketingProfile
Giulia KennedyChief Scientific Officer, Chief Medical OfficerProfile
Steven FrenchSenior OfficerProfile
Marc StapleyCEO DirectorProfile

About Veracyte Management Performance

The success or failure of an entity such as Veracyte often depends on how effective the management is. Veracyte management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Veracyte management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Veracyte management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis Prosigna Breast Cancer Assay for breast cancer diagnosis Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis and Immunoscore Colon Cancer test for colon cancer diagnosis. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. Veracyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 761 people.
Please note, the imprecision that can be found in Veracyte's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Veracyte. Check Veracyte's Beneish M Score to see the likelihood of Veracyte's management manipulating its earnings.

Veracyte Workforce Analysis

Traditionally, organizations such as Veracyte use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Veracyte within its industry.

Veracyte Manpower Efficiency

Return on Veracyte Manpower

Revenue Per Employee541K
Revenue Per Executive26.2M
Net Income Per Employee29.3K
Net Income Per Executive1.4M
Working Capital Per Employee356.4K
Working Capital Per Executive17.3M

Additional Tools for Veracyte Stock Analysis

When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.